- Home
- FORA vs CLSD Comparison
FORA vs CLSD Comparison
Compare FORA & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- CLSD
- Stock Information
- Founded
- FORA 2014
- CLSD 2011
- Country
- FORA United States
- CLSD United States
- Employees
- FORA N/A
- CLSD N/A
- Industry
- FORA Computer Software: Prepackaged Software
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- CLSD Health Care
- Exchange
- FORA Nasdaq
- CLSD Nasdaq
- Market Cap
- FORA 60.2M
- CLSD 68.4M
- IPO Year
- FORA N/A
- CLSD 2016
- Fundamental
- Price
- FORA $2.28
- CLSD $4.00
- Analyst Decision
- FORA Strong Buy
- CLSD Hold
- Analyst Count
- FORA 1
- CLSD 4
- Target Price
- FORA $5.00
- CLSD $4.33
- AVG Volume (30 Days)
- FORA 73.0K
- CLSD 670.5K
- Earning Date
- FORA 11-12-2025
- CLSD 11-11-2025
- Dividend Yield
- FORA N/A
- CLSD N/A
- EPS Growth
- FORA N/A
- CLSD N/A
- EPS
- FORA N/A
- CLSD N/A
- Revenue
- FORA $25,031,040.00
- CLSD $4,166,000.00
- Revenue This Year
- FORA $47.82
- CLSD $98.20
- Revenue Next Year
- FORA $10.11
- CLSD $213.77
- P/E Ratio
- FORA N/A
- CLSD N/A
- Revenue Growth
- FORA 18.59
- CLSD N/A
- 52 Week Low
- FORA $1.64
- CLSD $0.29
- 52 Week High
- FORA $4.03
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- FORA 61.78
- CLSD 96.25
- Support Level
- FORA $2.20
- CLSD $0.32
- Resistance Level
- FORA $2.38
- CLSD $0.36
- Average True Range (ATR)
- FORA 0.15
- CLSD 0.08
- MACD
- FORA 0.03
- CLSD 0.24
- Stochastic Oscillator
- FORA 78.43
- CLSD 89.60
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.